Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.21
+0.130012.04%
Post-market: 1.220.0100+0.83%19:59 EDT
Volume:972.60K
Turnover:1.14M
Market Cap:95.08M
PE:-1.89
High:1.22
Open:1.11
Low:1.09
Close:1.08
Loading ...

Company Profile

Company Name:
SELLAS Life Sciences Group Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
16
Office Location:
Times Square Tower,Suite 2503,7 Times Square,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

Directors

Name
Position
Angelos M. Stergiou
Director, President and Chief Executive Officer
Jane Wasman
Chair of the Board and Independent Director
John Varian
Independent Director
Robert L. Van Nostrand
Independent Director
David A. Scheinberg
Director

Shareholders

Name
Position
Angelos M. Stergiou
Director, President and Chief Executive Officer
Barbara A. Wood
Executive Vice President, General Counsel and Corporate Secretary
John T. Burns
Vice President, Finance and Corporate Controller